We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Resverlogix Corp. has announced that following recent meetings with various European regulatory bodies, the first confirmation for our Phase 3 clinical plan has officially been received.

A further regulatory and protocol design update will be provided to the market post the approval of additional regulatory bodies and the launch of our planned Phase 3 clinical trial entitled BETonMACE.

"This represents a momentous step forward in the clinical development of RVX-208," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "With this important regulatory confirmation now complete, we expect to launch the upcoming BETonMACE Phase 3 clinical trial this fall. The primary endpoint of the BETonMACE trial is designed to show a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE) in high-risk cardiovascular and diabetes mellitus (DM) patients, as we have seen in previous Phase 2 clinical trials with RVX-208," further stated Mr. McCaffrey.

Advertisement